Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.11 is 48% below its 5-year average of 0.21, around the middle of its 5-year range (-13.91–18.74).
As of the fiscal period ended Tuesday, June 30, 2026. 17.12% below its 12-month average of 0.13.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.11.
DEBT TO EQUITY RATIO
0.11
DEBT TO EQUITY RATIO AVG TTM
0.13
DEBT TO EQUITY RATIO AVG 3Y
-0.02
DEBT TO EQUITY RATIO AVG 5Y
0.21
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-17.12%
CURRENT VS 3Y AVG
+633.99%
CURRENT VS 5Y AVG
-47.52%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 512 covered companies
CURRENT VS SECTOR MEDIAN
-22.10%
vs the sector median at left
Ernexa Therapeutics Inc.
Market Cap
$4.23M
Debt to Equity Ratio
0.11
TTM Avg
0.13
3Y Avg
-0.02
5Y Avg
0.21
Market Cap
$4.43M
Debt to Equity Ratio
0.18
TTM Avg
0.73
3Y Avg
0.52
5Y Avg
0.35
Market Cap
$4.52M
Debt to Equity Ratio
0.90
TTM Avg
0.35
3Y Avg
0.23
5Y Avg
0.29
Market Cap
$4.50M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$4.01M
Debt to Equity Ratio
0.70
TTM Avg
0.62
3Y Avg
0.55
5Y Avg
2.94
Market Cap
$4.73M
Debt to Equity Ratio
0.02
TTM Avg
0.03
3Y Avg
0.03
5Y Avg
0.03
Market Cap
$4.96M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.02
5Y Avg
0.02
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | $4.23M | 0.11 | 0.13 | -0.02 | 0.21 |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.43M | 0.18 | 0.73 | 0.52 | 0.35 |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.52M | 0.90 | 0.35 | 0.23 | 0.29 |
| GRI Bio, Inc. (GRI)vs › | $4.20M | 0.00 | 0.02 | 0.03 | 0.03 |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.50M | 0.00 | 0.00 | 0.00 | 0.00 |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.01M | 0.70 | 0.62 | 0.55 | 2.94 |
| CalciMedica, Inc. (CALC)vs › | $4.72M | 0.00 | 0.00 | 0.00 | 0.92 |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.73M | 0.02 | 0.03 | 0.03 | 0.03 |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.96M | 0.00 | 0.00 | 0.02 | 0.02 |
| Eocene Ltd. (EOCN)vs › | $3.57M | N/A | N/A | N/A | N/A |
Debt/Equity
0.11
Current Ratio
2.01
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.11 |
| 2026-03-31 | 0.06 |
| 2025-12-31 | 0.20 |
| 2025-09-30 | 0.15 |
| 2025-06-30 | 0.13 |
| 2025-03-31 | -0.48 |
| 2024-12-31 | 0.40 |
| 2024-09-30 | -0.74 |
| 2024-06-30 | -5.77 |
| 2024-03-31 | -13.91 |
| 2023-12-31 | 18.74 |
| 2023-09-30 | 11.58 |
| 2023-06-30 | 9.63 |
| 2023-03-31 | 0.48 |
| 2022-12-31 | 0.34 |
| 2022-09-30 | 0.31 |
| 2022-06-30 | 0.19 |
| 2022-03-31 | 0.07 |
| 2021-12-31 | 0.11 |
| 2021-09-30 | 0.25 |
| 2021-06-30 | 0.10 |
| 2021-03-31 | -0.64 |
| 2020-12-31 | 0.38 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
